Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for prostate cancer: can hormone therapy boost targeted treatment?

NCT ID NCT06654336

First seen Nov 18, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study looks at men whose prostate cancer has come back in a few spots after radiation therapy. It compares two approaches: targeted treatment alone versus targeted treatment plus a hormone-blocking drug (ELIGARD). The goal is to see which combination delays cancer progression better. About 162 men will take part and be followed for 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, H1T2M4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Juravinski Cancer Centre

    RECRUITING

    Hamilton, Ontario, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Ottawa Hospital Regional Cancer Centre

    NOT_YET_RECRUITING

    Ottawa, Ontario, K1H8L6, Canada

    Contact

Conditions

Explore the condition pages connected to this study.